Dr. Ambily K (@drambilyk) header
Dr. Ambily K (@drambilyk) profile picture

MBBS MD DM. Consultant nephrologist, AIMS Thrissur. @glomcon fellow 2022-23. @KidneyKolumns EB member 2024-25. @winicon2024 #SoMe team.

Kerala, India
Joined April 2022
Photo by Dr. Ambily K (@drambilyk)Photo by Dr. Ambily K (@drambilyk)Photo by Dr. Ambily K (@drambilyk)Photo by Dr. Ambily K (@drambilyk)Photo by Dr. Ambily K (@drambilyk)Photo by Dr. Ambily K (@drambilyk)
An excellent #Onconephrology session with Dr @kdjhaveri on glomerular diseases in malignancy, followed by insightful case discussions by Dr @GuhanS1804 & Dr @drambilyk , with valuable perspectives from Dr @raja_1980. Great learning! 👏 #Glomerulonephritis #ISN_SAARC_OncoNeph
1
7
12
575
🎇Opening session of the ISN-SAARC Onconephrology Course 2026 begins with an insightful lecture by Dr. @kdjhaveri, moderated by Dr @vjha126. 🎉Excited to share our journey with our new bunch of candidates. #Onconephrology #NephTwitter
5
14
747
💥Kickstarting the ISN-SAARC Onconeph Course 2026 🎓 Introductory session on onconephrology by Dr @kdjhaveri 📍 Exploring the intersection of kidney disease and cancer care. #Onconephrology #Nephrology #MedicalEducation #KidneyHealth #CancerCare
8
9
591
Thrilled to announce the selected candidates for the ISN SAARC Onconephrology Fellowship 2026! Welcome to the cohort - ready to advance kidney care in cancer patients across the region. Congratulations to all! #ISNSAARC2026 #Onconephrology #Nephrology
4
13
27
2,050
Obesity in CKD: Core Curriculum 2026 ajkd.org/article/S0272-6386%…
1
100
1
247
11,707
🧠 Post Renal Transplant Infections Timeline – Must Know! 🕒 0–1 month (Surgical phase) • Nosocomial infections dominate • UTI, SSI, pneumonia • Not immunosuppression-driven 🕒 1–6 months (🔥 Peak immunosuppression) • Opportunistic infections • Cytomegalovirus infection (most common) • Pneumocystis jirovecii pneumonia, TB, fungi • BK virus nephropathy 🕒 >6 months (Community phase) • CAP, UTI, influenza • Late CMV, PCP (if no prophylaxis) • Post-transplant lymphoproliferative disorder 💡 Pearls: ✔ Timeline = diagnosis shortcut ✔ CMV = key player ✔ Think TB in India ✔ TMP-SMX prophylaxis saves lives #GSR #BuddingNephros #Transplant #Infection
3
77
2
191
7,107
Sunday morning quiz Which blood component has highest sensitizong event when given to kidney transplant recipients?🩸🩸 Is it A. PACKED RED BLOOD CELLS B. Whole blood C. Leucodepleted PCV D. Platelets ??? Platelets have upto 10* higher HLA expression 🩸🩸 Remember this next time you order SdP for ur patients
2
18
38
2,413
Dr. Ambily K retweeted
Optimal glucocorticoid therapy in lupus nephritis doi.org/10.1093/ndt/gfae294
60
171
6,607
🫀 Diuretic Resistance in Cardiorenal Syndrome: Are We Treating the Wrong Target? A recent review in Frontiers in Cardiovascular Medicine challenges a deeply ingrained paradigm in heart failure management: 👉 That congestion is simply a “fluid problem.” In reality, diuretic resistance (DR) is not failure of therapy, it is failure of understanding physiology. 🔬 The Core Insight Up to 1 in 3 HF patients will not respond adequately to loop diuretics. But the mechanism is not just “insufficient dose.” It is a multisystem adaptive response: ↓ Renal perfusion + ↑ venous congestion Tubular remodeling (distal sodium avidity) Neurohormonal activation (RAAS, SNS) Chloride depletion → a neglected driver of resistance 👉 We are not dealing with “volume overload” 👉 We are dealing with a sodium-retentive, neurohormonally activated organ ⚠️ The Clinical Mistake We still rely on: Weight Fluid balance Creatinine These are late, indirect, and often misleading markers. Meanwhile, the kidney has already adapted. 📊 The Paradigm Shift The paper reinforces a critical transition toward: 1. Physiology-guided monitoring Urinary sodium (UNa) at 1-2h Urine output kinetics POCUS (VExUS, lung ultrasound) 2. Mechanism-based therapy Sequential nephron blockade Chloride repletion (not just sodium restriction) Early combination strategies 3. Phenotype-specific management Not all HF is the same: Right heart failure → venous congestion-driven DR CKD → pharmacokinetic + tubular limitations Obesity → hidden congestion + inflammatory sodium retention Frailty → narrow therapeutic window 👉 Same drug, different physiology, different response 🧠 The Take-Home Message Diuretic resistance is not a pharmacologic problem. It is a systems physiology problem. And until we treat: Renal perfusion Venous congestion Electrolyte signaling (chloride!) Patient phenotype 👉 We will continue escalating doses… 👉 …instead of improving outcomes. 🚀 My Perspective We are moving toward a future where: UNa replaces weight as the primary feedback loop POCUS becomes mandatory, not optional If you're managing HF patients daily: Are you still chasing urine… or understanding the kidney? 📃Reference Aletras, G., etc al. Frontiers in Cardiovascular Medicine, 12, 1731305. doi.org/10.3389/fcvm.2025.17…
1
91
1
276
16,372
💊 How Tacrolimus Reduces Proteinuria – Tacrolimus works beyond immunosuppression 👇 🔹 🧬 Podocyte stabilization (KEY) Preserves synaptopodin → maintains actin cytoskeleton → ↓ foot process effacement → rapid ↓ proteinuria 🔹 🛡️ Anti-apoptotic effect Inhibits calcineurin–NFAT pathway → ↓ podocyte apoptosis → preserves podocyte number → slows progression 🔹 Immunological action ↓ T-cell activation & cytokines → ↓ immune-mediated glomerular injury 🔹 ⚖️ Hemodynamic effect (secondary) Afferent vasoconstriction → ↓ intraglomerular pressure → ↓ protein filtration #GSR #BuddingNephros #Nephrology #Tacrolimus #Proteinuria #Podocyte
2
111
210
8,443
💉DKA is not a glucose problem. It’s a metabolic collapse. We often simplify diabetic ketoacidosis as: ❌ “Severe hyperglycemia” But that’s misleading. 👉 You can have normal glucose and still be in DKA 1. What really defines DKA The classic triad: Hyperglycemia Anion gap metabolic acidosis Ketonemia But the key driver is: 👉 Insulin deficiency → unchecked ketogenesis 2. The dangerous trap: Euglycemic DKA Up to ~3% of patients present with: Glucose <250 mg/dL Severe acidosis High anion gap -Common triggers: SGLT2 inhibitors Pregnancy Starvation 👉 If you wait for hyperglycemia… 👉 You will miss it. 3. Think in triggers: the “5 I’s” Infection Infarction Insulin (non-adherence) Intoxication Infant (pregnancy) 👉 DKA is always a consequence, not the disease itself. 4. The physiology most people forget Total body potassium = LOW Serum potassium = often NORMAL or HIGH Why? 👉 Acidosis shifts K⁺ out of cells Then you give insulin → ⚠️ Potassium crashes 5. The biggest treatment mistake Stopping insulin too early. 👉 Insulin is NOT for glucose 👉 Insulin is for ketosis ⚠️ Never stop insulin until: Anion gap closes Bicarbonate normalizes 6. Fluids matter more than you think Patients are often: 👉 4–6 liters depleted And interestingly: Balanced crystalloids may improve outcomes⚠️ Avoid hyperchloremic acidosis 7. The mindset shift DKA management is not: ❌ “Lower glucose” It is: ✅ Stop ketogenesis ✅ Restore volume ✅ Correct electrolytes ✅ Treat the trigger 🤓Final message If you remember only one thing: 👉 Normal glucose does NOT exclude DKA 📃Reference Lowie BJ. Endocrinol Metab Clin N Am 55 (2026) 1–10 doi.org/10.1016/j.ecl.2025.0…
4
81
2
285
16,488
The five primary clinical presentations of Diabetic Neuropathies. It categorizes nerve damage based on the type of fibers affected and the anatomical distribution of symptoms. link.springer.com/rwe/10.100…
73
2
310
10,631
Dr. Ambily K retweeted
HF + CKD = treat by EF + eGFR 🎯 ✅HFrEF: <15 → β-blocker + nitrates 15–29 → + SGLT2i (>20) ± vericiguat 30–59 → + ARNI/ACEi/ARB + MRA ≥60 → full GDMT ✅HFpEF: SGLT2i backbone; add nsMRA (>25), ARNI if EF ~50% @goKDIGO pubmed.ncbi.nlm.nih.gov/4179…
1
148
5
395
17,076
Dr. Ambily K retweeted
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased #cardiovascular mortality compared with controlled blood pressure. 📄 Learn more in this Review: ja.ma/4bExPSl
67
168
10,942
Dr. Ambily K retweeted
KDIGO 2026 AKI/AKD guidelines Key takeaway kdigo.org/guidelines/acute-k…
2
169
2
485
22,811
Dr. Ambily K retweeted
KDIGO 2026 Diabetes and CKD guidelines . Key Points. kdigo.org/wp-content/uploads…
1
89
1
293
11,535
Dr. Ambily K retweeted
Membranous Nephropathy 🔬Anti-PLA2R= diagnosis,prognosis,monitoring 📊Risk stratify:Proteinuria+eGFR+PLA2R 🟢 Low risk→ Supportive 🟡 Mod→ Observe ± RTX 🔴 High→ Rituximab / Cyclophosphamide+Steroids 👍for Antigens: VA @KKNephBytes 💯 #Nephrology #KDIGO
26
74
2,370
Dr. Ambily K retweeted
🚨 Resistant Hypertension: From “Apparent” to “True” — Precision Matters (JAMA 2026) 🔬 Definition & Epidemiology — Not All Resistant HTN is Real Apparent resistant HTN = BP ≥130/80 mm Hg despite ≥3 drugs (ACEi/ARB + CCB + thiazide) at optimal doses ~20% of treated hypertensives fall into this category BUT → True resistant HTN ≈10% only after exclusion of: White-coat effect (~37.5%) Nonadherence (~50%) Secondary causes (~5–25%) 👉 Clinical message: Most “resistant HTN” is pseudo-resistant → diagnosis refinement is critical 🧠 Stepwise Diagnostic Algorithm (High-Yield Clinical Thinking) 1️⃣ Exclude White-Coat Effect Home BP <130/80 OR ABPM <125/75 mm Hg ➡️ Continue monitoring, no overtreatment 2️⃣ Assess Adherence (Underrated Step) Use refill data / drug assays Address: Cost barriers Adverse effects Cognitive issues 3️⃣ Screen Secondary Causes Primary aldosteronism (commonest) CKD, OSA, obesity, drugs (NSAIDs, SNRIs, cocaine) 👉 Only after this → TRUE resistant HTN confirmed ⚠️ Why It Matters (Prognostic Impact) ↑ Cardiovascular mortality risk (absolute ↑ ~10% over 5–10 yrs) Strong association with: Diabetes CKD Obesity Sleep apnea 🧬 Therapeutic Strategy — CME India Algorithmic Pearls 🔹 Step 1: Lifestyle (Foundation Therapy) Sodium <1500 mg/day Weight loss + exercise ≥150 min/week Avoid alcohol, offending drugs Treat OSA 👉 Often neglected but high-yield in India 🔹 Step 2: Optimize Triple Therapy Prefer single-pill combinations (↑ adherence, ↓ SBP ~4 mmHg) Diuretic optimization: Chlorthalidone > thiazide (especially CKD) Add loop diuretic if eGFR <30 🔹 Step 3: Add Mineralocorticoid Receptor Antagonist (MRA) — ⭐ GAME CHANGER Spironolactone 25–50 mg/day ↓ Office SBP: ~13 mmHg ↓ Ambulatory SBP: ~8 mmHg Criteria: eGFR ≥45 ml/min K⁺ ≤4.5 mmol/L 👉 Most effective add-on therapy in resistant HTN 🔹 If Spironolactone Intolerance Amiloride (non-inferior) Eplerenone (less potent, fewer endocrine effects) 🔹 Step 4: Sequential Add-ons β-blockers α1-blockers (doxazosin) Central agents (clonidine) Non-DHP CCB Vasodilators Aprocitentan (dual endothelin antagonist — emerging option) 🔹 Step 5: Device Therapy Renal denervation ↓ Ambulatory SBP ~4.4 mmHg ↓ Office SBP ~6.6 mmHg 👉 For selected refractory cases 💊 Drug Hierarchy (Practical Take-Home) 👉 Best Add-On: ✔️ Spironolactone > all others 👉 Alternatives: ✔️ Amiloride ≈ spironolactone ✔️ Eplerenone (safer endocrine profile) 👉 Less Effective / Add-on: β-blockers, α-blockers, clonidine 👉 New Kid: Aprocitentan (modest effect, fluid retention risk) ⚠️ Adverse Effect Awareness Spironolactone: Hyperkalemia (3–5%) Gynecomastia (~5–9%) Clonidine: Rebound HTN α-blockers: Orthostatic hypotension 🎯 CME INDIA CLINICAL PEARLS 🔴 “Resistant HTN is often diagnostic failure, not therapeutic failure” 🔴 “Half of resistant HTN = nonadherence → always check before escalating” 🔴 “Chlorthalidone + Spironolactone = backbone of resistant HTN therapy” 🔴 “Primary aldosteronism is underdiagnosed → think beyond essential HTN” 🔴 “Single-pill combinations are not convenience—they are outcome modifiers” 🔴 “Renal denervation: modest BP fall but useful in selected refractory cases” 📚 Key Reference (Journal Format) Carey RM, et al. Resistant Hypertension: Diagnosis and Management. JAMA. 2026; doi:10.1001/jama.2026.2846682 jamanetwork.com/journals/jam…
47
154
6,840
Dr. Ambily K retweeted
Hyponatremia
1
42
2
178
5,628